{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:31:39Z","timestamp":1780403499661,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00508-018-1359-3","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T07:35:26Z","timestamp":1531985726000},"page":"535-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Austrian recommendations for the management of polycythemia vera"],"prefix":"10.1007","volume":"130","author":[{"given":"Sonja","family":"Burgstaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Buxhofer-Ausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Beham-Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Krippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"W\u00f6lfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"1359_CR1","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et\u00a0al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia"},{"key":"1359_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajh.2830470205","volume":"47","author":"BJ Ania","year":"1994","unstructured":"Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ 3rd. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935\u20131989. Am J Hematol. 1994;47:89\u201393.","journal-title":"Am J Hematol"},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N\u00a0Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"1359_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et\u00a0al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"1359_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, Staerk J, Delhommeau F, Lacout C, et\u00a0al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et\u00a0al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"1359_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et\u00a0al. JAK2 eon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N\u00a0Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med"},{"key":"1359_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a\u00a0lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17:584\u201396.","journal-title":"Cancer Cell"},{"key":"1359_CR9","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","volume":"122","author":"S Hasan","year":"2013","unstructured":"Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, et\u00a0al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a\u00a0competitive advantage that is hampered by IFN alpha. Blood. 2013;122:1464\u201377.","journal-title":"Blood"},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","volume":"111","author":"R Tiedt","year":"2008","unstructured":"Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111:3931\u201340.","journal-title":"Blood"},{"key":"1359_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood-2015-12-689216","volume":"128","author":"J Grisouard","year":"2016","unstructured":"Grisouard J, Li S, Kubovcakaova L, Rao TN, Meyer SC, Lundberg P, et\u00a0al. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016;128:839\u201351.","journal-title":"Blood"},{"key":"1359_CR12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et\u00a0al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"1359_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Gugioelmelli P, Finke CM, Totunno G, Elala Y, et\u00a0al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"},{"key":"1359_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ajh.23474","volume":"88","author":"FP Siegel","year":"2013","unstructured":"Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol. 2013;88:665\u20139.","journal-title":"Am J Hematol"},{"key":"1359_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1055\/s-2007-996121","volume":"23","author":"JJ Michiels","year":"1997","unstructured":"Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost. 1997;23:441\u201354.","journal-title":"Semin Thromb Hemost"},{"key":"1359_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1046\/j.1365-2141.2002.03380.x","volume":"117","author":"G Torgano","year":"2002","unstructured":"Torgano G, Mandelli C, Massaro P, Abbiati C, Ponzetto A, Bertinieri G, et\u00a0al. Gastroduodenal lesions in polycythemia vera: frequency and role of Helicobacter pylori. Br J Haematol. 2002;117:198\u2013202.","journal-title":"Br J Haematol"},{"key":"1359_CR17","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1359_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ajh.23585","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, et\u00a0al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89:52\u20134.","journal-title":"Am J Hematol"},{"key":"1359_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.13080","volume":"167","author":"F Lussana","year":"2014","unstructured":"Lussana F, Carobbio A, Randi ML, Rumi EC, Finazzi G, et\u00a0al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythemia vera. Br J Haematol. 2014;167:541\u20136.","journal-title":"Br J Haematol"},{"key":"1359_CR20","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","volume":"119","author":"T Barbui","year":"2012","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, et\u00a0al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119:2239\u201341.","journal-title":"Blood"},{"key":"1359_CR21","first-page":"339","volume":"12","author":"NI Berlin","year":"1975","unstructured":"Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339\u201351.","journal-title":"Semin Hematol"},{"key":"1359_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J\u00a0Clin Oncol. 2011;29:761\u201370.","journal-title":"J Clin Oncol"},{"key":"1359_CR23","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et\u00a0al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574\u20139.","journal-title":"Leukemia"},{"key":"1359_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et\u00a0al. Cardiovascular events and intensity of treatment of polycythemia vera. N\u00a0Engl J Med. 2013;368:22\u201333.","journal-title":"N Engl J Med"},{"key":"1359_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJM198102193040801","volume":"304","author":"PD Berk","year":"1981","unstructured":"Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, et\u00a0al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil treatment. N\u00a0Engl J Med. 1981;304:441\u20137.","journal-title":"N Engl J Med"},{"key":"1359_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N\u00a0Engl J Med. 2004;350:114\u201324.","journal-title":"N Engl J Med"},{"key":"1359_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/09537100600758677","volume":"17","author":"JJ Michiels","year":"2006","unstructured":"Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Nemann HA, et al. Platelet-mediated erythromelalgia, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: Platelets. 2006;17:528\u201344. a\u00a0distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.","journal-title":"Platelets"},{"key":"1359_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1538-7836.2009.03686.x","volume":"8","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Randi ML, Morra E, Cazzola M. Aspirin in pregnant patients with essential thrombocythemia: a\u00a0retrospective analysis of 129 pregnancies. J\u00a0Thromb Haemost. 2010;8:411\u20133.","journal-title":"J. Thromb. Haemost."},{"key":"1359_CR29","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","volume":"117","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117:4706\u201315.","journal-title":"Blood"},{"key":"1359_CR30","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlurle P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065\u201372.","journal-title":"Blood"},{"key":"1359_CR31","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Manshuouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J\u00a0Clin Oncol. 2009;27:5418\u201324.","journal-title":"J Clin Oncol"},{"key":"1359_CR32","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a\u00a0novel IFN alfa-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762\u20139.","journal-title":"Blood"},{"key":"1359_CR33","first-page":"320","volume":"130","author":"H Gisslinger","year":"2017","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva L, Egyed M, et al. Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial. Blood. 2017;130:320.","journal-title":"Blood"},{"key":"1359_CR34","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","volume":"90","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain J\u2011D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370\u20137.","journal-title":"Blood"},{"key":"1359_CR35","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"29","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain J\u2011D. Treatment of polycythemia vera with Hydroxyurea and Pipibroman: final results of a\u00a0randomized trial initiated in 1980. J\u00a0Clin Oncol. 2011;29:3907\u201313.","journal-title":"J Clin Oncol"},{"key":"1359_CR36","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larran","year":"2016","unstructured":"Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, Perez-Encinas M, Ferrer-Marin F, Barez A, et al. Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythemia vera. Br J Haematol. 2016;172:786\u201393.","journal-title":"Br J Haematol"},{"key":"1359_CR37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.23160","volume":"87","author":"E Antonioli","year":"2012","unstructured":"Antonioli E, Gugliemelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, et al. Hydroxyurea-related toxicity in 3411 patients with Ph-negative MPN. Am J Hematol. 2012;87:552\u20134.","journal-title":"Am J Hematol"},{"key":"1359_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cncr.26194","volume":"118","author":"R Latagliata","year":"2012","unstructured":"Latagliata R, Spadea A, Cedrone M, Ki Giandonenico J, De Muro M, Villiv\u00e0 N, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the mister Hyde face of a\u00a0sage drug. Cancer. 2012;118:404\u20139.","journal-title":"Cancer"},{"key":"1359_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/cncr.28441","volume":"120","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, et\u00a0al. A phase 2 study of Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120:513\u201320.","journal-title":"Cancer"},{"key":"1359_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vanucchi","year":"2015","unstructured":"Vanucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et\u00a0al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N\u00a0Engl J Med. 2015;372:426\u201335.","journal-title":"N Engl J Med"},{"key":"1359_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly (RESPONSE-2): a\u00a0randomized, open-label, phase 3b study. Lancet Oncol. 2017;18:88\u201399.","journal-title":"Lancet Oncol"},{"key":"1359_CR42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","volume":"96","author":"AM Vanucchi","year":"2017","unstructured":"Vanucchi AM, Verstovsek S, Gugliemelli P, Griesshammer M, Burn TC, Naim A, et\u00a0al. Ruxolitnib reduces JAK2p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017;96:1113\u201320.","journal-title":"Ann Hematol"},{"key":"1359_CR43","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Brossart P, Wolf D. Ruxolitnibis a\u00a0potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122:3843\u20134.","journal-title":"Blood"},{"key":"1359_CR44","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275\u201390.","journal-title":"Br J Haematol"},{"key":"1359_CR45","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"JH Smalberg","year":"2012","unstructured":"Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a\u00a0meta-analysis. Blood. 2012;120:4921\u20138.","journal-title":"Blood"},{"key":"1359_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/MEG.0000000000000282","volume":"27","author":"A Mancuso","year":"2015","unstructured":"Mancuso A. An update on the management of Budd-Chiari-syndrome: the issues of timing and choice of treatment. Eur J Gastroenterol Hepatol. 2015;27:200\u20133.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1359_CR47","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1160\/th15-04-0326","volume":"115","author":"V Stefano De","year":"2016","unstructured":"De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost. 2016;115:240\u20139.","journal-title":"Thromb Haemost"},{"key":"1359_CR48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.blre.2008.03.007","volume":"22","author":"M Griesshammer","year":"2008","unstructured":"Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 2008;22:235\u201345.","journal-title":"Blood Rev"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-018-1359-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1359-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1359-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:33:46Z","timestamp":1571618026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-018-1359-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":48,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s00508-018-1359-3","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]},"assertion":[{"value":"31 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following authors declare that they have served as consultants or received speakers fees from industrial companies: S.\u00a0Burgstaller Novartis, AOP Orphan, K.\u00a0Geissler Novartis, AOP Orphan, H.\u00a0Gisslinger Novartis, AOP Orphan, Baxalta, Celgene, M.\u00a0Krauth Novartis, AOP Orphan, A.\u00a0W\u00f6lfler Novartis, AOP. V.\u00a0Buxhofer-Ausch, T.\u00a0Sliwa, C.\u00a0Beham-Schmid, G.\u00a0Gastl, T.\u00a0Melchardt, P.\u00a0Krippl, A.\u00a0Petzer and H.\u00a0Rumpold declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}